Nanopath: $25 Million Series B To Advance Women’s Health Molecular Testing

Nanopath has raised $25 million in Series B financing to advance a 15-minute molecular test for vaginitis and prepare its point-of-care diagnostics platform for potential commercialization. The round includes $2 million in nondilutive grant funding and was co-led by Norwest and SV Health Investors’ MedTech Convergence Fund. The Labcorp Venture Fund participated alongside Elderberry Ventures, GingerBread Capital, Alumni Ventures, and other investors.

Nanopath has now raised more than $46 million. Catherine Kiani of Elderberry Ventures and Mindy Nye of Labcorp Diagnostics joined the company’s board as observers in connection with the financing.

The company developed an optical biosensing platform that performs molecular detection without the nucleic acid amplification required by traditional PCR tests. Nanopath believes this approach can deliver laboratory-quality results more quickly at a clinical point of care.

The funding will support manufacturing scale-up and the initiation of an FDA 510(k) clinical study for Nanopath’s vaginitis assay. The company will also expand its clinical and commercial teams ahead of a potential product launch.

Delivering results during a single patient visit could allow clinicians to select treatment using molecular information instead of relying on symptoms or sending samples to a centralized laboratory.

Nanopath intends to expand its platform into tests for urinary tract infections and sexually transmitted infections. Its broader objective is to make sophisticated molecular diagnostics more accessible while improving diagnostic accuracy in areas of women’s health that have received limited investment.

The vaginitis test remains under development and has not been cleared or approved by the FDA. Commercial availability depends on successful development, clinical testing, and regulatory review.

KEY QUOTES:

“Nanopath is developing truly transformative technology with the potential to reshape the molecular diagnostics industry and dramatically improve patient outcomes.”

Jeff Crowe, Senior Managing Partner at Norwest

“We’ve spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long. This funding brings us closer to the next and most important step—translating that innovation into meaningful clinical impact.”

Alison Burklund, PhD, Co-Founder and Co-Chief Executive Officer of Nanopath

“We’re incredibly proud of the extraordinary team we’ve built at Nanopath and our shared commitment to transforming women’s healthcare.”

Amogha Tadimety, PhD, Co-Founder and Co-Chief Executive Officer of Nanopath